| This long-term, randomized, open-label trial in Japanese patients with chronic or episodic migraine found that fremanezumab was associated with no drug-related serious adverse events, or deaths reported during the 12-month study period. |
| The most common adverse events related to fremanezumab treatment were nasopharyngitis and injection-site reactions; antidrug antibody development was infrequent. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.